Grants Search Results

Based on progress to date, Dr. Fish was awarded a new grant in 2011 to fund an additional two years of this Scholar award. Since over 75% of children with cancer can now be cured, the population of 250,000 survivors of childhood cancer in the USA is rapidly growing. Over 60% of survivors have a chronic medical problem, and 27% a severe or life-threatening problem as a result of their treatment. Research into problems faced by survivors is critical to improving their care. Dr. Fish investigates whether care in a specialized center will improve: 1) patient awareness of treatments they received and risks they face because of those treatments; and 2) the ability of survivors to follow medical recommendations and referrals.

Based on progress to date, Dr. Hermiston was awarded a new grant in 2011 to fund an additional two years of this Scholar award. Almost all patients who have relapsed leukemia or lymphoma will die. Dr. Hermiston's research is to find a way to predict which of these patients with T-cell malignancies are likely to relapse, so those children can be given the aggressive treatments they need upon diagnosis, and those not likely to relapse can avoid the long-term side effects of unnecessarily aggressive treatments.

Based on progress to date, Dr. Janeway was awarded a new grant in 2011 to fund an additional two years of this Scholar award. Osteosarcoma is the most common primary bone tumor in children, yet 80% of metastatic cases remain incurable. (Metastatic means it has "spread" beyond the primary site, in this case the bones.) No therapeutic advances have been made for two decades. Dr. Janeway's research is to find drugs that cause osteosarcoma to act more like normal bone than like cancer; find ways to halt the progression to metastatic osteosarcoma; and develop a useful testing ground for drugs to treat metastatic osteosarcoma.

Based on progress to date, Nina Kadan-Lottick, M.D., M.S.P.H., TeamBrent St. Baldrick's Scholar, was awarded a new grant in 2012 to fund an additional two years of this Scholar award. About 25-30% of survivors of childhood cancer will experience long-term impairment in cognitive abilities and emotional regulation. Dr. Kadan-Lottick's research is to identify the reasons for the considerable variation in outcomes among children who received identical therapy, possibly inherited factors that affect how chemotherapy is metabolized or that result in a general vulnerability to these outcomes.

This grant is named for TeamBrent, created in 2005 to fight childhood cancer alongside then three-year-old Brent who was battling stage IV neuroblastoma; TeamBrent has since raised more than $3.5 million for childhood cancer research through the St. Baldrick's Foundation.

Based on progress to date, Dr. Keating was awarded a new grant in 2011 to fund an additional two years of this Scholar award. Brain tumors are the most common solid tumor of pediatrics and are a leading cause of cancer related deaths. Astrocytoma is a brain tumor that has no effective chemotherapies and the survival rates for high-grade astrocytoma remain well below 10%. Identification of new potential treatment targets is the goal of Dr. Keating's project.

Based on progress to date, Dr. Paz-Priel was awarded a new grant in 2011 to fund an additional two years of this Scholar award. Acute myelogenous leukemia (AML) is the third leading cause of cancer related mortality in children. Only about half of the children with AML are cured with current approaches. Dr. Paz-Priel is working to identify how these cancer cells resist chemotherapy and survive, with the ultimate result of helping to find ways to cure these children.